» LEARN ABOUT COVID-19 VARIANTS, VACCINES, TESTING, & VISITOR REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

COG-AEWS1031

Trial

Clinical Trial Title

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Trial Status

Closed to Enrollment

Start Date

November 1, 2010

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Ewing Sarcoma (Non-Metastatic)

Description

This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma.

Eligibility Criteria

Age less than or equal to 50 years

Newly diagnosed, biopsy confirmed, extracranial, non-metastatic Ewing sarcoma or PNET (Primitive neuroectodermal tumor) of bone or soft tissue

No prior chemotherapy or radiation therapy is allowed

Adquate kidney, liver, and heart function

Notes

https://clinicaltrials.gov/ct2/show/NCT01231906

Study status is:
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program

Phone

(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:12 AM